Allergic conjunctivitis: An update on diagnosis and management

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 5, 2013, Pages 543-549

  O'Brien, Terrence P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic conjunctivitis; Ocular allergy; Perennial allergic conjunctivitis; Seasonal allergic conjunctivitis

Indexed keywords

AK CON; ALCAFTADINE; ALL CLEAR; ALLERGEN; ANTAZOLINE V; ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; AZELASTINE; BEPOTASTINE; CROMOGLYCATE DISODIUM; DEGEST; EMEDASTINE; EPINASTINE; ESTIVIN II; EYE ITCH RELIEF; EYE OINTMENT; KETOROLAC TROMETAMOL; KETOTIFEN FUMARATE; LEVOCABASTINE; LODOXAMIDE TROMETAMOL; LORATADINE; LOTEPREDNOL ETABONATE; NAPHAZOLINE; NAPHAZOLINE PLUS PHENIRAMINE MALEATE; NEDOCROMIL; OCU ZOLINE; OLOPATADINE; PEMIROLAST; TETRYZOLINE; UNCLASSIFIED DRUG; VASOCLEAR; VASOCON A;

ALLERGY TEST; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL FACTOR; HUMAN; MEDICAL ASSESSMENT; MEDICAL HISTORY; PERENNIAL ALLERGIC CONJUNCTIVITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEASONAL ALLERGIC CONJUNCTIVITIS;

ADRENAL CORTEX HORMONES; ANIMALS; CONJUNCTIVITIS, ALLERGIC; DECISION MAKING; DISEASE PROGRESSION; HISTAMINE ANTAGONISTS; HUMANS; LUBRICANTS; SEASONS; VASOCONSTRICTOR AGENTS;

EID: 84883598722     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328364ec3a     Document Type: Review

References (46)

1. Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115:118-122.
2. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011; 11:471-476.
3. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86):8-160.
4. Kari O, Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy 2010; 3:149-158.
5. Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol 2000; 106:1019-1032.
6. Butrus S, Portela R. Ocular allergy: Diagnosis and treatment. Ophthalmol Clin North Am 2005; 18:485-492; v.
7. Raizman MB, Luchs JI, Shovlin JP, Wolf RL. Ocular allergy: A scientific review and expert case debate. Rev Ophthalmol 2012; URL http://www.revoptom-com/ continuing-education/tabviewtest/lessonid/108286/.
8. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Conjunctivitis: Limited revision. San Francisco, CA: American Acedemy of Ophthalmology; 2011.
9. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosaassociated lymphoid tissue. Cancer 1984; 53:2515-2524.
10. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008; 28:43-58; v.i.
11. Moloney G, McCluskey PJ. Classifying and managing allergic conjunctivitis. Med Today 2007; 8:16-21.
12. Alexander M, Berger W, Buchholz P, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005; 3:67.
13. Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: A case series of 195 patients with long-term followup. Ophthalmology 2000; 107:1157-1163.
14. Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am 2008; 28:1-23.
15. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 2006; 25:900-907.
16. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108:84-88.
17. Moller C, Bjorksten B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984; 39:37-41.
18. Gomes P, Abelson MB. Comparison of environmental and allergen-challenge based assessments of allergic conjunctivitis treatment using an antihistaminesteroid combination therapy. J Allergy Clin Immunol 2012; 129:S718.
19. Bielory BP, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: Guide to therapy. Acta Ophthalmol 2012; 90:399-407.
20. Simons FE, Simons KJ. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139-1150 e1134.
21. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008; 122:S1-S84.
22. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 min and 16 h after instillation versus placebo and olopatadine 0.1% Clin Ophthalmol 2011; 5:87-93.
23. Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin 2011; 27:623-631.
24. Williams PB, Crandall E, Sheppard JD. Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clin Ophthalmol 2010; 4:993-1001.
25. Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis: A double-blind, randomized, placebocontrolled study. Allergy 1998; 53:857-862.
26. Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003; 19:321-329.
27. Carr WW, Nayak AS, Ratner PH, et al. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc 2013; 34:247-254.
28. Meier EJ, Torkildsen GL, Gow JA, et al. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc 2012; 33:265-274.
29. McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol 2012; 6:1731-1738.
30. Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009; 31:1908-1921.
31. Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 2010; 150:122-127 e125.
32. Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: A randomized, double-masked, parallel-group, active- and vehiclecontrolled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004; 26:29-34.
33. Friedlaender MH. Epinastine in the management of ocular allergic disease. Int Ophthalmol Clin 2006; 46:85-86.
34. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797-804.
35. Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000; 78:60-63.
36. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211-218.
37. Bielory L, Katelaris CH, Lightman S, Naclerio RM. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. Med-GenMed 2007; 9:35.
38. Shulman DG, Amdahl L, Washington C, Graves A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Ther 2003; 25:1096-1106.
39. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998; 7:266-269.
40. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: A retrospective study. Acta Ophthalmol Scand 2006; 84:693-695.
41. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 2007; 26:1035-1038.
42. Restasis [package insert]. Irvine, CA: Allergan, Inc; 2004.
43. Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: What is new?. Curr Opin Allergy Clin Immunol 2009; 9:477-481.
44. Koberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. CurrOpin Allergy Clin Immunol 2011; 11:192-199.
45. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: A systematic classification. J Glaucoma 2003; 12:393-398.
46. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11:17-33.